→
Molina Healthcare Inc
Molina Healthcare (MOH) is currently facing significant challenges, evidenced by a staggering EPS growth decline of 58.21% year-over-year alongside three consecutive earnings misses, including a Q4 2025 actual EPS of -$2.75 against an estimate of $0.337. The company's current price of $145.88 stands well below its 52-week high of $351.95, which indicates a weakening market sentiment around its growth potential. Additionally, with a P/E ratio of 15.85 and a P/S ratio of only 0.16, the valuation metrics suggest limited upside considering the current operational struggles.
Given the recent performance and ongoing challenges, I recommend a cautious stance on MOH stock.
CMS Issues Guidance On New Limits For Federal Medicaid & CHIP Funding Restrictions For Noncitizens
2026-04-08
UnitedHealth, Humana, CVS Jump As CMS Boosts Medicare Payments
2026-04-07
Shares of health insurance companies are trading higher after CMS announced a 2.48% rate hike for Medicare Advantage
2026-04-07
Medicare Finalizes 2.48% Rate Hike For Private Insurers In 2027
2026-04-06
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes your holdings, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates MOH as Bearish. Given the recent performance and ongoing challenges, I recommend a cautious stance on MOH stock.
The recent earnings misses indicate a troubling trend, with Q4 2025 showing a significant miss by $3.087, raising concerns about management's ability to execute effectively. Furthermore, the 58.21% decline in EPS growth year-over-year suggests that the company may struggle to regain investor confidence in the near term.
If Molina can turn around its earnings trajectory and capitalize on the recent 2.48% rate hike for Medicare Advantage, revenue growth could potentially accelerate beyond the current 11.75%. Additionally, if the company manages to address its operational inefficiencies, there might be a chance to recover closer to its 52-week high of $351.95.
Molina Healthcare (MOH) is currently facing significant challenges, evidenced by a staggering EPS growth decline of 58.21% year-over-year alongside three consecutive earnings misses, including a Q4 2025 actual EPS of -$2.75 against an estimate of $0.337. The company's current price of $145.88 stands well below its 52-week high of $351.95, which indicates a weakening market sentiment around its growth potential. Additionally, with a P/E ratio of 15.85 and a P/S ratio of only 0.16, the valuation metrics suggest limited upside considering the current operational struggles.
Molina Healthcare (MOH) is currently facing significant challenges, evidenced by a staggering EPS growth decline of 58.21% year-over-year alongside three consecutive earnings misses, including a Q4 2025 actual EPS of -$2.75 against an estimate of $0.337. The company's current price of $145.88 stands well below its 52-week high of $351.95, which indicates a weakening market sentiment around its growth potential. Additionally, with a P/E ratio of 15.85 and a P/S ratio of only 0.16, the valuation metrics suggest limited upside considering the current operational struggles. Our overall verdict is Bearish.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for MOH at helmterminal.dev/analyze/MOH, updated continuously during US market hours. No signup required.